Compare OMI & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMI | TMCI |
|---|---|---|
| Founded | 1882 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.3M | 174.6M |
| IPO Year | N/A | 2021 |
| Metric | OMI | TMCI |
|---|---|---|
| Price | $2.80 | $2.49 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 5 |
| Target Price | ★ $6.46 | $4.96 |
| AVG Volume (30 Days) | ★ 1.9M | 903.1K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,768,859,000.00 | $218,879,000.00 |
| Revenue This Year | N/A | $3.25 |
| Revenue Next Year | N/A | $0.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 132.03 | 7.90 |
| 52 Week Low | $2.38 | $2.36 |
| 52 Week High | $15.54 | $10.79 |
| Indicator | OMI | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 32.97 |
| Support Level | $2.60 | $2.40 |
| Resistance Level | $2.79 | $2.56 |
| Average True Range (ATR) | 0.17 | 0.16 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 29.41 | 22.40 |
Owens & Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products & Healthcare Services segment.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.